tetano
Editor, Senior Moderator
Am J Physiol Lung Cell Mol Physiol
. 2020 Jun 10.
doi: 10.1152/ajplung.00199.2020. Online ahead of print.
Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities
Joseph Alan Hippensteel[SUP] 1 [/SUP], Wells B LaRiviere[SUP] 2 [/SUP], James F Colbert[SUP] 1 [/SUP], Christophe J Langou?t-Astri?[SUP] 1 [/SUP], Eric P Schmidt[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus Disease 2019 (COVID-19), the clinical syndrome associated with infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has impacted nearly every country in the world. Despite an unprecedented focus of scientific investigation, there is a paucity of evidence-based pharmacotherapies against this disease. Due to this lack of data-driven treatment strategies, broad variations in practice patterns have emerged. Observed hypercoagulability in COVID-19 patients has created debate within the critical care community on the therapeutic utility of heparin. We seek to provide an overview of the data supporting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. Additionally, we review preclinical evidence establishing biological plausibility for heparin and synthetic heparin-like drugs as therapies for COVID-19 through anti-viral and anti-inflammatory effects. Finally, we discuss known adverse effects and theoretical off-target effects that may temper enthusiasm for the adoption of heparin as a therapy in COVID-19 without confirmatory prospective randomized controlled trials. Despite previous failures of anticoagulants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness of this therapy.
Keywords: COVID-19; Heparin; Venous Thromboembolism.
. 2020 Jun 10.
doi: 10.1152/ajplung.00199.2020. Online ahead of print.
Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities
Joseph Alan Hippensteel[SUP] 1 [/SUP], Wells B LaRiviere[SUP] 2 [/SUP], James F Colbert[SUP] 1 [/SUP], Christophe J Langou?t-Astri?[SUP] 1 [/SUP], Eric P Schmidt[SUP] 1 [/SUP]
Affiliations
- PMID: 32519894
- DOI: 10.1152/ajplung.00199.2020
Abstract
Coronavirus Disease 2019 (COVID-19), the clinical syndrome associated with infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has impacted nearly every country in the world. Despite an unprecedented focus of scientific investigation, there is a paucity of evidence-based pharmacotherapies against this disease. Due to this lack of data-driven treatment strategies, broad variations in practice patterns have emerged. Observed hypercoagulability in COVID-19 patients has created debate within the critical care community on the therapeutic utility of heparin. We seek to provide an overview of the data supporting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. Additionally, we review preclinical evidence establishing biological plausibility for heparin and synthetic heparin-like drugs as therapies for COVID-19 through anti-viral and anti-inflammatory effects. Finally, we discuss known adverse effects and theoretical off-target effects that may temper enthusiasm for the adoption of heparin as a therapy in COVID-19 without confirmatory prospective randomized controlled trials. Despite previous failures of anticoagulants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness of this therapy.
Keywords: COVID-19; Heparin; Venous Thromboembolism.